6UI.F ARECOR THERAPEUTICS -01
- Market cap
- EUR 36.7M
- P/E
- 81.0x
- P/B
- 8.32x
- ROE
- 10.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 6UI.F undervalued?
Graham numberThe Graham number of ARECOR THERAPEUTICS -01 cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ARECOR THERAPEUTICS -01 fundamental analysis
No fundamental analysis for ARECOR THERAPEUTICS -01 yet.
ARECOR THERAPEUTICS -01 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ARECOR THERAPEUTICS -01
Arecor Therapeutics plc, a clinical stage biotechnology company, develops therapeutics that address diabetes, obesity and other cardiometabolic diseases in the United Kingdom. The company's lead therapeutic product is the AT278, a disruptor insulin which is designed to transform Automated Insulin Delivery (AID) systems to improve patient care for people living with diabetes. It also develops a novel oral delivery platform using a GLP-1 receptor agonist. Arecor Therapeutics p…
Full company profileARECOR THERAPEUTICS -01 financial statements
ARECOR THERAPEUTICS -01 annual financial statements (GBP; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 1.16M | 2.40M | 4.57M | 1.64M | 1.71M |
| Gross Profit | 1.16M | - | 1.25M | 919K | 1.27M |
| Operating Income | -6.44M | -10.5M | -9.18M | -5.18M | -4.05M |
| EBITDA | - | -10.1M | -8.39M | -4.72M | 1.22M |
| Net Income | -6.17M | -9.26M | -8.55M | -10.2M | 664K |
| EPS | -0.22 | -0.30 | -0.28 | -0.27 | 0.02 |
| Balance Sheet | |||||
| Total Assets | 20.9M | 21.8M | 15.4M | 8.72M | 8.10M |
| Total Liabilities | 2.37M | 4.31M | 5.85M | 3.37M | 1.65M |
| Shareholders' Equity | 18.5M | 17.5M | 9.53M | 5.35M | 6.45M |
| Cash & Short-term Investments | 18.3M | 4.77M | 5.09M | 3.24M | 3.00M |
| Cash Flow | |||||
| Operating Cash Flow | -5.45M | -10.8M | -5.84M | -9.33M | -2.36M |
| Capital Expenditure | 69.0K | 345K | 151K | 8.00K | 99.0K |
| Free Cash Flow | -5.52M | -11.1M | -5.99M | -9.34M | -2.46M |
| Ratios | |||||
| ROE | -33.3% | -53.1% | -89.8% | -191.4% | 10.3% |
| ROA | -29.5% | -42.5% | -55.6% | -117.4% | 8.2% |
| Net Profit Margin | -532.7% | -385.4% | -187.1% | -623.0% | 38.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ARECOR THERAPEUTICS -01 dividends
ARECOR THERAPEUTICS -01 has not paid dividends in the last 5 fiscal years.
Who owns ARECOR THERAPEUTICS -01
- Insiders 28.46%
- Institutions 41.93%
- Public & others 29.61%
- Shares outstanding 45.3M
- Free float 23.3M
ARECOR THERAPEUTICS -01 company profile
- Company name
- ARECOR THERAPEUTICS -01
- Ticker
- 6UI.F
- ISIN
- GB00BMWLM973
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 33
- Fiscal year end
- December
- Address
- Chesterford Research Park, Little Chesterford, United Kingdom, CB10 1XL
- Phone
- 44 1223 426 060
- Website
- arecor.com
About ARECOR THERAPEUTICS -01
Arecor Therapeutics plc, a clinical stage biotechnology company, develops therapeutics that address diabetes, obesity and other cardiometabolic diseases in the United Kingdom. The company's lead therapeutic product is the AT278, a disruptor insulin which is designed to transform Automated Insulin Delivery (AID) systems to improve patient care for people living with diabetes. It also develops a novel oral delivery platform using a GLP-1 receptor agonist. Arecor Therapeutics plc was founded in 2007 and is headquartered in Little Chesterford, the United Kingdom.
ARECOR THERAPEUTICS -01 management
4- Dr. Sarah Jennifer Howell Ph.D.CEO & Executive Director · born 1975
- Mr. David J. EllamCFO & Executive Director · born 1964
- Dr. Jan Jezek Ph.D.Chief Scientific Officer
- Mr. David GerringChief Development Officer